In trials studying the use of<unk>  after acute stroke, there was an increased risk of "serious adverse events" requiring hospitalization. These were specifically defined as: :"...any untoward medical occurrence that, at any dose, resulted in death, was life‐threatening, required inpatient hospitalisation or resulted in prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event or reaction”.
Cerebrolysin
Embelin
Amyloid beta
Retapamulin
Apamin
Tetraspanin
Glutamate-rich protein 3
Neurofilament light polypeptide